newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//NDTV Profit
Eli Lilly announced that its targeted therapy Retevmo (selpercatinib) significantly reduced the risk of disease recurrence or death in patients with early-stage RET fusion-positive non-small cell lung cancer.
Retevmo reduced the risk of recurrence or death by 83% in early-stage RET-positive NSCLC patients.
KEY POINTS
LIBRETTO-432 is the first randomized Phase 3 trial of a selective RET inhibitor in the adjuvant setting.
Event-free survival at 24 months was 92% with Retevmo versus 61% with placebo in stage II-IIIA patients.
RET fusions are now considered key actionable biomarkers alongside EGFR mutations and ALK fusions in early-stage lung cancer.
Lilly plans to submit trial data to regulators, potentially establishing Retevmo as a new standard of care.
In a promising breakthrough for lung cancer treatment, Eli Lilly announced that its targeted therapy Retevmo (selpercatinib) significantly reduced the risk of disease recurrence or death in patients with early-stage RET fusion-positive non-small cell lung cancer (NSCLC), according to results from a Phase 3 clinical trial.
The LIBRETTO-432 study found that patients treated with Retevmo after surgery or radiation therapy experienced an 83% lower risk of cancer recurrence or death compared with those receiving a placebo, according to a press release.
The trial involved 151 patients with stage IB-IIIA RET fusion-positive NSCLC and is the first randomized Phase 3 study to evaluate a selective RET inhibitor in the adjuvant setting.
According to the company, event-free survival rates at 24 months reached 92% among patients with stage II-IIIA disease who received Retevmo, compared with 61% in the placebo group.
ALSO READ : India, Oman Trade Pact To Come Into Force From June 1: An Explainer
Similar benefits were observed across the broader study population, reinforcing the drug's potential role in preventing cancer relapse.
The findings, which will be presented at the 2026 Annual Meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, highlight the growing importance of comprehensive genomic testing in lung cancer diagnosis.
Researchers said the results place RET fusions alongside EGFR mutations and ALK fusions as key biomarkers that can be effectively targeted in early-stage lung cancer. While overall survival data remain immature, early trends also favoured Retevmo.
ALSO READ : 'No Trust In Promises': Iran's Chief Negotiator Rules Out US Deal Without Tangible Results
Lilly said it plans to submit the trial data to global regulatory authorities, a move that could pave the way for Retevmo to become a new standard treatment option for patients with early-stage RET-positive lung cancer.